S&P 500   4,345.45 (+0.36%)
DOW   34,103.26 (+0.10%)
QQQ   360.89 (+0.85%)
AAPL   176.51 (+1.48%)
MSFT   318.99 (-0.17%)
META   301.38 (+1.91%)
GOOGL   131.57 (+0.87%)
AMZN   130.60 (+0.98%)
TSLA   252.81 (-1.13%)
NVDA   417.98 (+1.90%)
NIO   8.52 (+0.83%)
BABA   88.23 (+4.90%)
AMD   97.43 (+1.37%)
T   15.20 (-0.72%)
F   12.53 (+2.70%)
MU   69.55 (+2.43%)
CGC   0.83 (+8.72%)
GE   112.49 (-0.44%)
DIS   82.12 (-0.74%)
AMC   7.99 (+3.77%)
PFE   32.69 (-0.49%)
PYPL   58.61 (-0.02%)
NFLX   382.24 (-0.50%)
S&P 500   4,345.45 (+0.36%)
DOW   34,103.26 (+0.10%)
QQQ   360.89 (+0.85%)
AAPL   176.51 (+1.48%)
MSFT   318.99 (-0.17%)
META   301.38 (+1.91%)
GOOGL   131.57 (+0.87%)
AMZN   130.60 (+0.98%)
TSLA   252.81 (-1.13%)
NVDA   417.98 (+1.90%)
NIO   8.52 (+0.83%)
BABA   88.23 (+4.90%)
AMD   97.43 (+1.37%)
T   15.20 (-0.72%)
F   12.53 (+2.70%)
MU   69.55 (+2.43%)
CGC   0.83 (+8.72%)
GE   112.49 (-0.44%)
DIS   82.12 (-0.74%)
AMC   7.99 (+3.77%)
PFE   32.69 (-0.49%)
PYPL   58.61 (-0.02%)
NFLX   382.24 (-0.50%)
S&P 500   4,345.45 (+0.36%)
DOW   34,103.26 (+0.10%)
QQQ   360.89 (+0.85%)
AAPL   176.51 (+1.48%)
MSFT   318.99 (-0.17%)
META   301.38 (+1.91%)
GOOGL   131.57 (+0.87%)
AMZN   130.60 (+0.98%)
TSLA   252.81 (-1.13%)
NVDA   417.98 (+1.90%)
NIO   8.52 (+0.83%)
BABA   88.23 (+4.90%)
AMD   97.43 (+1.37%)
T   15.20 (-0.72%)
F   12.53 (+2.70%)
MU   69.55 (+2.43%)
CGC   0.83 (+8.72%)
GE   112.49 (-0.44%)
DIS   82.12 (-0.74%)
AMC   7.99 (+3.77%)
PFE   32.69 (-0.49%)
PYPL   58.61 (-0.02%)
NFLX   382.24 (-0.50%)
S&P 500   4,345.45 (+0.36%)
DOW   34,103.26 (+0.10%)
QQQ   360.89 (+0.85%)
AAPL   176.51 (+1.48%)
MSFT   318.99 (-0.17%)
META   301.38 (+1.91%)
GOOGL   131.57 (+0.87%)
AMZN   130.60 (+0.98%)
TSLA   252.81 (-1.13%)
NVDA   417.98 (+1.90%)
NIO   8.52 (+0.83%)
BABA   88.23 (+4.90%)
AMD   97.43 (+1.37%)
T   15.20 (-0.72%)
F   12.53 (+2.70%)
MU   69.55 (+2.43%)
CGC   0.83 (+8.72%)
GE   112.49 (-0.44%)
DIS   82.12 (-0.74%)
AMC   7.99 (+3.77%)
PFE   32.69 (-0.49%)
PYPL   58.61 (-0.02%)
NFLX   382.24 (-0.50%)
NASDAQ:CALA

Calithera Biosciences (CALA) Stock Forecast, Price & News

$0.05
0.00 (0.00%)
(As of 12:14 PM ET)
Compare
Today's Range
$0.05
$0.05
50-Day Range
$0.02
$0.08
52-Week Range
$0.01
$3.68
Volume
550 shs
Average Volume
136,955 shs
Market Capitalization
$243,500.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CALA stock logo

About Calithera Biosciences (NASDAQ:CALA) Stock

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

CALA Price History

CALA Stock News Headlines

From Naval Flight Officer to CEO
First Female Founded, Publicly Traded, Space Company. Discover more
Christina Cala
CALA - Calithera Biosciences, Inc.
Cala Mariolu
From Naval Flight Officer to CEO
First Female Founded, Publicly Traded, Space Company. Discover more
Cala Llombards
Calithera Biosciences to Liquidate >CALA
See More Headlines
Receive CALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CALA Company Calendar

Last Earnings
11/08/2021
Today
9/22/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CALA
Fax
N/A
Employees
8
Year Founded
2010

Profitability

Net Income
$-39,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$9.75 million
Book Value
($0.40) per share

Miscellaneous

Free Float
4,550,000
Market Cap
$243,500.00
Optionable
Optionable
Beta
0.28

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Susan M. Molineaux Ph.D. (Age 69)
    Founder, CEO, Pres & Director
    Comp: $625.81k
  • Ms. Stephanie Wong (Age 49)
    CFO & Sec.
    Comp: $752.42k
  • Dr. Christopher J. Molineaux Ph.D. (Age 70)
    Sr. VP of Devel.
  • Mr. Frank Parlati Ph.D. (Age 54)
    Sr. VP of Research
  • Dr. Susan B. Demo Ph.D.
    Sr. VP of R&D Operations
  • Dr. Allison Dillon Ph.D.
    Sr. VP of Commercial & Portfolio Strategy













CALA Stock - Frequently Asked Questions

Should I buy or sell Calithera Biosciences stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CALA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALA, but not buy additional shares or sell existing shares.
View CALA analyst ratings
or view top-rated stocks.

How have CALA shares performed in 2023?

Calithera Biosciences' stock was trading at $3.26 at the beginning of 2023. Since then, CALA shares have decreased by 98.5% and is now trading at $0.05.
View the best growth stocks for 2023 here
.

When is Calithera Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our CALA earnings forecast
.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($3.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.60) by $1.60. The biotechnology company had revenue of $6.75 million for the quarter. During the same period last year, the company earned ($6.40) earnings per share.

When did Calithera Biosciences' stock split?

Shares of Calithera Biosciences reverse split before market open on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE).

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How do I buy shares of Calithera Biosciences?

Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $0.05.

How much money does Calithera Biosciences make?

Calithera Biosciences (NASDAQ:CALA) has a market capitalization of $243,500.00 and generates $9.75 million in revenue each year. The biotechnology company earns $-39,650,000.00 in net income (profit) each year or ($25.60) on an earnings per share basis.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.calithera.com. The biotechnology company can be reached via phone at (650) 870-1000 or via email at ir@calithera.com.

This page (NASDAQ:CALA) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -